Abstract
Novel antineoplastic therapies have greatly improved cancer survival; nevertheless they are bringing in new forms of cardiomyopathy, that can often limit proper cancer treatments. Novel cardioprotective therapies are therefore needed, for improving clinical outcomes in cancer patients. In order to test novel therapeutic strategies, there is an increasing need for appropriate experimental models of chemotherapy-induced cardiomyopathy. Induced pluripotent stem (iPS) cell- and human embryonic stem cell (hESC )-derived cardiomyocytes may be used as alternative in vitro models for studying mechanisms that underly chemotherapy-induced cardiomyopathy. In this review we discuss the use of iPS- and hESC-derived cardiomyocytes for evaluating additional pharmacological targets and for predicting chemotherapy-induced cardiotoxicity.
Keywords: Cardiac stem cells, chemotherapy-induced cardiotoxicity, pluripotent stem cells, preclinical models, cardiomyopathy, human embryomic stem cell.
Current Drug Targets
Title:Modelling Chemotherapy-induced Cardiotoxicity by Human Pluripotent Stem Cells
Volume: 18 Issue: 6
Author(s): Rosalinda Madonna*, Christian Cadeddu, Martino Deidda, Paolo Spallarossa, Concetta Zito and Giuseppe Mercuro*
Affiliation:
- Dipartimento di Scienze Mediche Mario Aresu, Universita of Cagliari,Italy
- Department of Medical Sciences “Mario Aresu”, University of Cagliari, Cagliari,Italy
Keywords: Cardiac stem cells, chemotherapy-induced cardiotoxicity, pluripotent stem cells, preclinical models, cardiomyopathy, human embryomic stem cell.
Abstract: Novel antineoplastic therapies have greatly improved cancer survival; nevertheless they are bringing in new forms of cardiomyopathy, that can often limit proper cancer treatments. Novel cardioprotective therapies are therefore needed, for improving clinical outcomes in cancer patients. In order to test novel therapeutic strategies, there is an increasing need for appropriate experimental models of chemotherapy-induced cardiomyopathy. Induced pluripotent stem (iPS) cell- and human embryonic stem cell (hESC )-derived cardiomyocytes may be used as alternative in vitro models for studying mechanisms that underly chemotherapy-induced cardiomyopathy. In this review we discuss the use of iPS- and hESC-derived cardiomyocytes for evaluating additional pharmacological targets and for predicting chemotherapy-induced cardiotoxicity.
Export Options
About this article
Cite this article as:
Madonna Rosalinda*, Cadeddu Christian, Deidda Martino, Spallarossa Paolo, Zito Concetta and Mercuro Giuseppe *, Modelling Chemotherapy-induced Cardiotoxicity by Human Pluripotent Stem Cells, Current Drug Targets 2017; 18 (6) . https://dx.doi.org/10.2174/1389450117666160401125404
DOI https://dx.doi.org/10.2174/1389450117666160401125404 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Health Benefits of Honey: Implications for Treating Cardiovascular Diseases
Current Nutrition & Food Science Potential Therapeutic Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in the Context of Ischemic Heart Failure: A State-of-the-Art Review
Cardiovascular & Hematological Agents in Medicinal Chemistry Oxidative and Inflammatory Events in Prion Diseases: Can They Be Therapeutic Targets?
Current Aging Science Cardiac Stem Cell-Based Myocardial Regeneration: Towards a Translational Approach
Cardiovascular & Hematological Agents in Medicinal Chemistry Etiopathogenesis, Classical Immunotherapy and Innovative Nanotherapeutics for Inflammatory Neurological Disorders
Current Nanoscience Bioactive Compounds in Diabetic Cardiomyopathy: Current Approaches and Potential Diagnostic and Therapeutic Targets
Cardiovascular & Hematological Agents in Medicinal Chemistry Daunorubicin Metabolism in Leukemic Cells Isolated from Patients with Acute Myeloid Leukemia
Drug Metabolism Letters Natural Products as a Paradigm for the Treatment of Coxsackievirus - induced Myocarditis
Current Topics in Medicinal Chemistry Good at Heart: Preserving Cardiac Metabolism during aging
Current Diabetes Reviews An Overview of Piperazine Scaffold as Promising Nucleus for Different Therapeutic Targets
Current Pharmaceutical Design Homocysteine and Heart Failure: An Overview
Recent Patents on Cardiovascular Drug Discovery Type 2 Diabetes and Heart Failure: Challenges and Solutions
Current Cardiology Reviews Cardiovascular Side Effects of New Antidepressants and Antipsychotics: New Drugs, old Concerns?
Current Pharmaceutical Design Contrast Echocardiography: An Update on Clinical Applications
Current Pharmaceutical Design How Cardiomyocytes Make the Heart Old
Current Pharmaceutical Biotechnology Cardiac Telocytes
Current Stem Cell Research & Therapy Macrovascular Complications of Type 2 Diabetes Mellitus
Current Vascular Pharmacology Tissue Protective and Anti-Fibrotic Actions of Suramin: New Uses of an Old Drug
Current Clinical Pharmacology Interrelationship Between Kidney Function and Percutaneous Mitral Valve Interventions: A Comprehensive Review
Current Cardiology Reviews Intracellular Calcium Homeostasis and Kidney Disease
Current Medicinal Chemistry